glp-1 weight loss - Search News

News

Daily weight loss pill sees success in trials

U.S. News & World Report · 6h

1 in 10 Americans Has Used GLP-1 Drugs For Weight Loss, Survey Says

By Dennis Thompson HealthDay ReporterFRIDAY, Aug. 8, 2025 (HealthDay News) — More than 1 in 10 Americans have used a GLP-1 drug for weight loss, a new survey by the RAND research group reveals. About 12% say they’ve tried GLP-1 drugs, like Ozempic, Wegovy or Zepbound, with rates of use highest among people ages 50 to 64, survey results show.

The Washington Post on MSN · 22h

GLP-1 weight-loss pills are coming. So are doubts about their potency.

Next-generation weight-loss pills could hit the market in the coming months, with new data raising a key question: Will patients embrace a more convenient alternative to injecting themselves, even if it means losing less weight?

Daily weight loss pill sees success in trials: Eli Lilly

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this year.

ConsumerAffairs1h

GLP-1 use surges among perimenopausal women but research hasn't kept up

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

6hon MSN

New weight loss pill more ‘tolerable’ than jabs shown to be effective in key trial

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed ...

Medical News Today1d

Muscle loss from GLP-1 drugs like Ozempic may not be as high as thought

A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

1d

Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.

The science behind ‘Ozempic face’: How to improve GLP-1-related skin sagging

GLP-1 receptor agonists are associated with risk reductions for dozens of diseases and conditions in addition to rapid weight ...

InvestorsHub on MSN5h

Novo Nordisk Shares Climb for Second Day as Lilly’s Obesity Pill Falls Short of Wegovy in Trial

Shares of Novo Nordisk (NYSE:NVO), traded in Copenhagen, rose over 5% on Friday, extending gains from the previous session.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results